On August 30, 2018 the Norwegian biotech company Ultimovacs AS took over the immunotherapy technology business of the Swedish company Immuneed AB last month (Press release, Ultimovacs, AUG 30, 2018, View Source [SID1234536998]). The complementary technologies of the two companies provide a unique platform for development of novel vaccine solutions for treatment and possibly prevention of cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The acquired business has been named Ultimovacs AB and is now a fully-owned Swedish subsidiary of Ultimovacs AS. The business is located in Uppsala and has two employees.

"In Ultimovacs, we have been looking for an adjuvant technology that can further improve cancer vaccines. Simultaneously, Immuneed has been searching for a peptide based vaccine platform for further testing of their technology. This is a perfect match", says Øyvind Kongstun Arnesen, CEO of Ultimovacs.

Ultimovacs is a Norwegian pharmaceutical company developing novel immunotherapies against cancer. The lead product candidate is UV1, a peptide-based vaccine inducing a specific T cell response against the universal cancer antigen telomerase. UV1 is currently in clinical testing in the US. The purchase price of the technology business of Immuneed AB was NOK 50.4 million, corresponding to SEK 54.5 million, which was paid partly in cash and partly in shares in Ultimovacs AS. "We are very excited about this merger. By joining forces with Ultimovacs, with their promising cancer vaccine and significant experience from clinical development, we believe the potential of the TET platform technology can be realized and benefit patients faster and better", says Camilla Huse Bondesson, Chairman of the Board of Immuneed AB.

The value of the Immuneed technology to Ultimovacs

Based on an exclusive license agreement with the Leiden University Medical Centre, Immuneed has developed technology (named the ‘TET-platform’) that Ultimovacs believes can attractively complement the cancer vaccine under development by Ultimovacs.

The TET-platform addresses the general challenge of so called "adjuvants" that enhance the desired response of the immune system to a vaccine. It makes it possible to incorporate adjuvant and the vaccine itself into one molecule. When using the technology from Immuneed, the antibodies formed by a previous vaccine can function as adjuvant for a new vaccine. This principle is general and can be applied as an adjuvant for many different vaccines. The principle and the technology have been successfully validated in different pre-clinical models.

Ultimovacs considers the TET-platform technology as a promising and general strategy to strengthen and increase T cell responses against cancer vaccine peptides. In parallel with the continued development of the therapeutic cancer vaccine UV1, Ultimovacs will therefore pursue the development of a new first-in-class cancer vaccine solution based on the proprietary TET-platform technology.

On August 30, 2018 Checkpoint Therapeutics, Inc. ("Checkpoint") (NASDAQ: CKPT), a Fortress Biotech (NASDAQ: FBIO) company, reported that James F. Oliviero, President and Chief Executive Officer of Checkpoint, will present a company overview at the 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC, on Wednesday, September 5, 2018, at 10 a.m. EDT (Press release, Checkpoint Therapeutics, AUG 30, 2018, View Source [SID1234529161]). The conference will be held at the St. Regis New York in New York City.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be available on the Events page of the Investors & Media section of Checkpoint’s website: www.checkpointtx.com.

On August 30, 2018 Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, reported that an overview of the company’s business strategy and commercial and development-stage programs will be given at two upcoming conferences being held in New York on September 5th and September 6th (Press release, Spectrum Pharmaceuticals, AUG 30, 2018, View Source [SID1234529178]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

20th Annual Rodman & Renshaw Global Investment Conference
When: Wednesday, September 5, 2018 at 10:25 AM ET
Baird’s 2018 Global Healthcare Conference
When: Thursday, September 6, 2018 at 1:25 PM ET

The presentations will be webcast live and may be accessed by visiting Spectrum’s website at View Source

On August 21, 2018 Triumvira Immunologics, Inc. (Triumvira), a privately-held biopharmaceutical company focused on designing safe and more effective T cell therapies, reported that it will present data today on its novel T cell therapy technology, TAC-T, during an oral presentation in the Adoptive T Cell Therapies session of the 6th Annual Immuno-Oncology Summit held in Boston (Press release, Triumvira Immunologics, AUG 30, 2018, View Source [SID1234529196]). The presentation will describe the differentiated mechanism of action of the company’s T cell antigen coupler (TAC) technology in preclinical studies demonstrating strong efficacy in both solid and liquid tumors with an improved safety profile compared to traditional CAR-T approaches.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The oral presentation, entitled: TAC-T: a novel T cell therapy, co-opts the endogenous T cell receptor for effective, safe, and persistent tumor rejection, will be delivered by Christopher Helsen, PhD, Director of Research and Development at Triumvira. Results from pre-clinical studies with human T cells engineered with Triumvira’s proprietary TAC technology directed against different antigens will be presented. The data suggest that TAC-T cells destroy tumor cells via a mechanism that mimics the natural process of T cell activation. Results clearly demonstrate efficient infiltration and proliferation in solid tumors resulting in rapid and sustained tumor regression in mice without toxicity. Furthermore, in a xenograft model of multiple myeloma, treated mice showed resistance to tumor re-challenge indicating long-term persistence of TAC-T cells.

"These results will further illustrate the potential of TAC-T cells, both in terms of efficacy and safety but also with respect to TAC T-cell persistence, a key point under consideration in T cell therapy," said Paul Lammers, MD, MSc, President and Chief Executive Officer.

Triumvira also announces it is participating in the 11th Annual International Partnering Conference BioPharm America on September 5-6 and the 4th Annual CAR-TCR Summit 2018 – Changing Lives with CAR-T & TCR Cell Immunotherapies on September 4-5, both being held during Biotech Week Boston. For more information, or to set up a meeting with Triumvira at either conference email: [email protected].

On August 30, 2018 IntelGenx Technologies Corp. (TSX-V:IGX) (OTCQX:IGXT) (the "Company" or "IntelGenx") reported that its Chief Financial Officer, Andre Godin, is scheduled to present at the Rodman & Renshaw 20th Annual Global Investment Conference on September 6, 2018 at 2:35 p.m. Eastern Time at the St. Regis New York (Press release, IntelGenx, AUG 30, 2018, View Source;Renshaw-Global-Investment-Conference/default.aspx [SID1234529179]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Mr. Godin will provide an overview of IntelGenx’s business during the presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.

The presentation will be webcast live and archived for 90 days on the Company’s website, www.intelgenx.com, under "Investors".